JOHNSON & JOHNSON MEDICAL SAS : revenue, balance sheet and financial ratios

JOHNSON & JOHNSON MEDICAL SAS is a French company founded 44 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in ISSY-LES-MOULINEAUX (92130), this company of category GE shows in 2024 a revenue of 458.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - JOHNSON & JOHNSON MEDICAL SAS (SIREN 612030619)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue 458 579 019 € 445 943 960 € 426 042 633 € 407 524 027 € 362 841 277 € 417 002 291 € 424 184 192 € 454 073 610 € 348 492 812 €
Net income 24 296 002 € 17 332 690 € 17 547 908 € 12 519 607 € 8 966 157 € 15 877 600 € 16 200 324 € 18 491 383 € 13 127 482 €
EBITDA 15 168 640 € 20 462 903 € 22 835 663 € 23 320 742 € 19 859 208 € 26 386 598 € 17 287 517 € 18 005 310 € -3 603 803 €
Net margin 5.3% 3.9% 4.1% 3.1% 2.5% 3.8% 3.8% 4.1% 3.8%

Revenue and income statement

In 2024, JOHNSON & JOHNSON MEDICAL SAS achieves revenue of 458.6 M€. Revenue is growing positively over 9 years (CAGR: +3.5%). Vs 2023: +3%. After deducting consumption (293.8 M€), gross margin stands at 164.8 M€, i.e. a rate of 36%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 15.2 M€, representing 3.3% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 24.3 M€, i.e. 5.3% of revenue. This profit can be retained or distributed to shareholders.

Revenue (2024) ?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production

458 579 019 €

Gross margin (2024) ?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed

164 779 764 €

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

15 168 640 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

25 608 851 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

24 296 002 €

EBITDA margin (2024) ?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability
5-10% : Average
< 5% : Low

3.3%

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 32%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 0.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.007%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

32.452%

Cash flow / Revenue (2024) ?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates

0.52%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

0.002

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

37.1%

Solvency indicators evolution
JOHNSON & JOHNSON MEDICAL SAS

Sector positioning

Debt ratio
0.01 2024
2022
2023
2024
Q1: 0.0
Med: 4.27
Q3: 43.96
Excellent -50 pts over 3 years

In 2024, the debt ratio of JOHNSON & JOHNSON MEDICAL... (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.

Financial autonomy
32.45% 2024
2022
2023
2024
Q1: 14.64%
Med: 38.36%
Q3: 60.56%
Average +19 pts over 3 years

In 2024, the financial autonomy of JOHNSON & JOHNSON MEDICAL... (32.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
0.0 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 1.09 years
Good -29 pts over 3 years

In 2024, the repayment capacity of JOHNSON & JOHNSON MEDICAL... (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 174.58. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 298.9x. Operating income very largely covers interest expenses: high safety margin.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

174.584

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

298.925

Liquidity indicators evolution
JOHNSON & JOHNSON MEDICAL SAS

Sector positioning

Liquidity ratio
174.58 2024
2022
2023
2024
Q1: 132.74
Med: 202.27
Q3: 325.9
Average -35 pts over 3 years

In 2024, the liquidity ratio of JOHNSON & JOHNSON MEDICAL... (174.58) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
298.93x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.41x
Q3: 6.25x
Excellent +17 pts over 3 years

In 2024, the interest coverage of JOHNSON & JOHNSON MEDICAL... (298.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 70 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 56 days. The company must finance 14 days of gap between collections and payments. Overall, WCR represents 108 days of revenue, i.e. 138.1 M€ to permanently finance. Notable WCR improvement over the period (-68%), freeing up cash.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

138 142 344 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

70 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

56 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR in days of revenue (2024) ?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management

108 j

WCR and payment terms evolution
JOHNSON & JOHNSON MEDICAL SAS

Positioning of JOHNSON & JOHNSON MEDICAL SAS in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of JOHNSON & JOHNSON MEDICAL SAS is estimated at 38 630 076 € (range 19 931 564€ - 122 757 307€). With an EBITDA of 15 168 640€, the sector multiple of 0.7x is applied. The price/revenue ratio is 0.21x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
124 transactions
19931k€ 38630k€ 122757k€
38 630 076 € Range: 19 931 564€ - 122 757 307€
NAF 5 all-time

Valuation detail by method

Ajustez les pondérations selon votre analyse

EBITDA Multiple 50%
15 168 640 € × 0.7x
Estimation 10 676 980 €
5 047 389€ - 38 860 313€
Revenue Multiple 30%
458 579 019 € × 0.21x
Estimation 97 665 592 €
52 961 736€ - 295 830 683€
Net Income Multiple 20%
24 296 002 € × 0.8x
Estimation 19 959 546 €
7 596 747€ - 72 889 731€

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare JOHNSON & JOHNSON MEDICAL SAS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about JOHNSON & JOHNSON MEDICAL SAS

What is the revenue of JOHNSON & JOHNSON MEDICAL SAS ?

The revenue of JOHNSON & JOHNSON MEDICAL SAS in 2024 is 458.6 M€.

Is JOHNSON & JOHNSON MEDICAL SAS profitable?

Yes, JOHNSON & JOHNSON MEDICAL SAS generated a net profit of 24.3 M€ in 2024.

Where is the headquarters of JOHNSON & JOHNSON MEDICAL SAS ?

The headquarters of JOHNSON & JOHNSON MEDICAL SAS is located in ISSY-LES-MOULINEAUX (92130), in the department Hauts-de-Seine.

Where to find the tax return of JOHNSON & JOHNSON MEDICAL SAS ?

The tax return of JOHNSON & JOHNSON MEDICAL SAS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does JOHNSON & JOHNSON MEDICAL SAS operate?

JOHNSON & JOHNSON MEDICAL SAS operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.